Travere Therapeutics (TVTX) CEO sells 60,000 shares after option exercise

Rhea-AI Filing Summary

Travere Therapeutics CEO Eric M. Dube reported planned option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on June 16, 2025. On January 23 and January 27, 2026, he exercised employee stock options for a total of 60,000 shares of common stock at an exercise price of $15.46 per share and sold the same number of shares at weighted average prices of $30.0127 and $30.097, respectively. Following these transactions, he held 419,173 shares of Travere common stock directly, and continued to hold fully vested employee stock options with a $15.46 exercise price expiring on January 31, 2030, including positions of 171,865 and 120,000 options.

Insider Trade Summary

Net Seller: 60,000 shares ($1,805,134)

Net Sell 6 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 60,000 shs ($1.81M)

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	51,865	$0.00	--
Exercise	Common Stock	51,865	$15.46	$802K
Sale	Common Stock	51,865	$30.097	$1.56M
Exercise	Employee stock option (right to buy)	8,135	$0.00	--
Exercise	Common Stock	8,135	$15.46	$126K
Sale	Common Stock	8,135	$30.0127	$244K

Holdings After Transaction: Employee stock option (right to buy) — 120,000 shares (Direct); Common Stock — 471,038 shares (Direct)

Footnotes (1)

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		M		8,135	A	$15.46	427,308	D
Common Stock	01/23/2026		S(1)		8,135	D	$30.0127(2)	419,173	D
Common Stock	01/27/2026		M		51,865	A	$15.46	471,038	D
Common Stock	01/27/2026		S(1)		51,865	D	$30.097(3)	419,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$15.46	01/23/2026		M			8,135	(4)	01/31/2030	Common Stock	8,135	$0	171,865	D
Employee stock option (right to buy)	$15.46	01/27/2026		M			51,865	(4)	01/31/2030	Common Stock	51,865	$0	120,000	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TVTX CEO Eric M. Dube report?

Eric M. Dube reported exercising employee stock options and selling Travere Therapeutics (TVTX) common stock. On January 23 and 27, 2026, he exercised options for 60,000 shares at $15.46 per share and sold the same number of shares at weighted average prices around $30.

How many Travere Therapeutics (TVTX) shares did the CEO sell and at what prices?

The CEO sold 60,000 shares of Travere Therapeutics common stock in total. Sales occurred at weighted average prices of $30.0127 on January 23, 2026 and $30.097 on January 27, 2026, with detailed price breakdowns available upon request to the company or SEC staff.

Were Eric M. Dube’s TVTX stock sales under a Rule 10b5-1 plan?

Yes, the sales were made under a written Rule 10b5-1 trading plan. The plan was adopted on June 16, 2025 and is designed to allow pre-arranged trading of shares, helping insiders diversify holdings while following Securities Exchange Act requirements and avoiding discretionary trade timing.

What is the exercise price and expiration of the TVTX employee stock options?

The reported employee stock options have an exercise price of $15.46 per share and are fully vested and exercisable. These options expire on January 31, 2030, giving the reporting person several years to exercise remaining grants, subject to Travere’s equity plan and applicable regulations.

How many Travere Therapeutics (TVTX) shares does the CEO own after these transactions?

After the reported transactions, Eric M. Dube directly owned 419,173 shares of Travere Therapeutics common stock. He also continued to hold employee stock options with a $15.46 exercise price expiring in 2030, including positions of 171,865 and 120,000 options.

What types of securities were involved in the TVTX Form 4 filing?

The Form 4 covered non-derivative common stock and derivative employee stock options. Options with a $15.46 exercise price were exercised into common shares, which were then sold in open-market transactions at weighted average prices slightly above $30 per share.